REC-1/iRFP stable cell line

REC-1/iRFP cells are derived from the human B-cell lymphoma cell line REC-1 by stably integration of a constitutive miRFP670 stably expression construct. REC-1 is derived from a patient with mantle cell lymphoma (MCL), making it a valuable model for studying this specific type of lymphoma. REC-1 cells are used to investigate the molecular pathways involved in MCL pathogenesis, including the role of cyclin D1 in cell cycle regulation, as well as to evaluate the efficacy of new therapeutic agents, including chemotherapy and targeted therapies. REC-1/iRFP cells stably express miRFP670, can be used for in vitro assays and in vivo imaging.